MindBio Therapeutics (XCNQ:MBIO) EBITDA Margin % : 40.10% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. MindBio Therapeutics's EBITDA for the three months ended in Mar. 2024 was C$0.15 Mil. MindBio Therapeutics's Revenue for the three months ended in Mar. 2024 was C$0.38 Mil. Therefore, MindBio Therapeutics's EBITDA margin for the quarter that ended in Mar. 2024 was 40.10%.

MindBio Therapeutics EBITDA Margin % Historical Data

The historical data trend for MindBio Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics EBITDA Margin % Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

EBITDA Margin %

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial					-	-	-	44.63	40.10

Competitive Comparison of MindBio Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, MindBio Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's EBITDA Margin % falls into.

MindBio Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

MindBio Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-3.42	/	0
	=	%

MindBio Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0.154	/	0.384
	=	40.10 %

MindBio Therapeutics (XCNQ:MBIO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

MindBio Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.